Trial intelligence / Profile preview

Phase 2 open-label HM61713 study in T790M-positive NSCLC after prior EGFR-TKI

2015-001435-21Phase 2Terminated

Sponsor

Hanmi Pharmaceutical

Start

Jul 2015

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1